Velicept Therapeutics Raises an Additional $15 Million in Series B Round, Initiates Phase 2b Study Evaluating Once Daily Dosing of Solabegron in Patients with Overactive Bladder (OAB) and Receives Issuance of Additional U.S. Patent -Additional Funding to Advance Phase 2b Development Program in OAB- -Enrollment for Second Phase 2 Study Well Underway- -Issuance of U.S. Patent No.